Alpha Wave Ventures
VC Fund
Miami, United States
Alpha Wave Ventures is an investment firm.
- Total investments:
- 28
- Last investment:
- Lead investor:
- 71%
Last updated:
For AI agents: llms.txt
Industries Alpha Wave Ventures invests in
Stages Alpha Wave Ventures invests in
Countries Alpha Wave Ventures invests in
Round sizes
Round size
- Series B
- $25M–$215M
- Series C
- $8.6M–$100M
- Series D
- $58M–$102M
Investment Focus
Industry
- Health Care 5 (18%)
- Medical 4 (14%)
- Biotechnology 4 (14%)
- Software 3 (11%)
- Biopharma 3 (11%)
Stage
- Series C 8 (29%)
- Series B 4 (14%)
- Series D 3 (11%)
- Seed 2 (7%)
- Series A 2 (7%)
Country
- United States 10 (36%)
- India 4 (14%)
- Israel 1 (4%)
- Hong Kong 1 (4%)
- United Kingdom 1 (4%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Cour Pharmaceuticals Development Co Inc operates in the pharmaceutical sector. Cour Pharmaceuticals Development Co Inc was founded in 2012 and is based in Elmhurst, Illinois. | $50M / Series B / Jun 18, 2026 | ||
| Cerebras Systems is a startup backed by premier venture capitalists and the industry’s most successful technologists. They are serially successful entrepreneurs dedicated to solving problems others are afraid to tackle. They value integrity, passion, real world problem solving ability, and a sense of humor. | $1.1B / Series G / Sep 30, 2025 | ||
| HistoSonics provides the Edison Platform, which uses advanced imaging and proprietary sensing technology to deliver non-invasive, personalized treatments with precision and control, and uses the science of histotripsy and focused sound energy to generate pressures to liquify and completely destroy targeted tissues at sub-cellular levels. | Private Equity / Aug 07, 2025 | ||
|
I-Ven Realty
|
I-Ven Realty is a joint venture of Oberoi Realty. | $146.4M / Secondary Market / May 10, 2025 | |
| Biolinq is a digital health platform developer that aims to create a pipeline of biomonitoring solutions. The company's platform includes a skin-applied, minimally invasive electrochemical biosensor that analyzes biomarkers in the interstitial fluid to provide actionable health information while continuously monitoring multiple biomarkers,allowing diabetic patients to monitor their blood glucose levels. | $100M / Series C / Mar 19, 2025 | ||
| Metsera operates as a clinical-stage biopharmaceutical company. | $215M / Series B / Nov 13, 2024 | ||
| HistoSonics provides the Edison Platform, which uses advanced imaging and proprietary sensing technology to deliver non-invasive, personalized treatments with precision and control, and uses the science of histotripsy and focused sound energy to generate pressures to liquify and completely destroy targeted tissues at sub-cellular levels. | $102M / Series D / Aug 15, 2024 | ||
| Biolinq is a digital health platform developer that aims to create a pipeline of biomonitoring solutions. The company's platform includes a skin-applied, minimally invasive electrochemical biosensor that analyzes biomarkers in the interstitial fluid to provide actionable health information while continuously monitoring multiple biomarkers,allowing diabetic patients to monitor their blood glucose levels. | $58M / Series D / Apr 04, 2024 | ||
| Hunch is a social discovery app that creates social interactions and honest discussions through anonymous conversations and polls and helps users meet new people and share opinions. | $23M / Series A / Mar 06, 2024 | ||
| Attralus is a biopharmaceutical company focusing on creating transformative medicines to improve the lives of patients with systemic amyloidosis. Its proprietary peptide-based pan-amyloid targeting agents have the potential to diagnose and treat all forms and stages of systemic amyloidosis. The company is focused on targeting common pathology inall systemic amyloidosis diseases, with the goal of developing treatments for all subtypes of amyloidosis, including the majority in which there are currently no treatment options. | $56M / Series B / Feb 06, 2024 | ||
| See all 28 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Alpha Wave Ventures invest in?
Alpha Wave Ventures invests primarily in Health Care, Medical and Biotechnology startups, most often at Series C and Series B stage. Most of the 28 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Alpha Wave Ventures's check size?
Alpha Wave Ventures typically joins rounds of $25M–$215M at Series B, $8.6M–$100M at Series C and $58M–$102M at Series D. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Alpha Wave Ventures participates in.
When did Alpha Wave Ventures last invest?
The most recent investment recorded for Alpha Wave Ventures closed in Jun 2026. Shizune tracks 28 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
